PE20080319A1 - Dihidrotienopirimidinas como agentes inhibidores de pde-4 - Google Patents
Dihidrotienopirimidinas como agentes inhibidores de pde-4Info
- Publication number
- PE20080319A1 PE20080319A1 PE2007000470A PE2007000470A PE20080319A1 PE 20080319 A1 PE20080319 A1 PE 20080319A1 PE 2007000470 A PE2007000470 A PE 2007000470A PE 2007000470 A PE2007000470 A PE 2007000470A PE 20080319 A1 PE20080319 A1 PE 20080319A1
- Authority
- PE
- Peru
- Prior art keywords
- 5lambda4
- pyrimidin
- dihydro
- phenyl
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE TIENOPIRIMIDINA DE FORMULA 1, DONDE X ES SO O SO2; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ARILO C6-C10, ENTRE OTROS; R2 ES H, ALQUILO C1-C10, ALQUENILO C2-C6, ENTRE OTROS; R3 ES OH, Cl, NITRILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {2-[4-(4-CLORO-FENIL)-PIPERAZINI-1-IL]-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-4-IL}-(3-MORFOLIN-4-ILMETIL-FENIL)-AMINA, TRIFLUOROACETATO DE (R)-N2-{2-[4-(4-CLORO-FENIL)-PIPERAZIN-1-IL]-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-4-IL)-3-METIL-BUTAN-1,2-DIAMINA, 4-{4-[4-(3-FLUORO-FENILAMINO)-5-OXO-6,7-DIHIDRO-5H,5LAMBDA4-TIENO[3,2-d]PIRIMIDIN-2-IL]-PIPERAZIN-1-IL}-N,N-DIMETILBENCENSULFONAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE PDE-4 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES O DE LAS VIAS RESPIRATORIAS, ENFERMEDADES INFLAMATORIAS DE LAS ARTICULACIONES, PIEL, OJOS, ENTRE OTRAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06112779A EP1847543A1 (de) | 2006-04-19 | 2006-04-19 | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080319A1 true PE20080319A1 (es) | 2008-05-13 |
Family
ID=36847643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000470A PE20080319A1 (es) | 2006-04-19 | 2007-04-17 | Dihidrotienopirimidinas como agentes inhibidores de pde-4 |
Country Status (20)
Country | Link |
---|---|
US (3) | US8114878B2 (es) |
EP (2) | EP1847543A1 (es) |
JP (1) | JP5214588B2 (es) |
KR (1) | KR20090009885A (es) |
CN (1) | CN101426505A (es) |
AR (1) | AR060516A1 (es) |
AU (1) | AU2007239573A1 (es) |
BR (1) | BRPI0710459A2 (es) |
CA (1) | CA2647243A1 (es) |
CO (1) | CO6140032A2 (es) |
EA (1) | EA200802051A1 (es) |
EC (1) | ECSP088738A (es) |
IL (1) | IL194739A0 (es) |
MX (1) | MX2008012915A (es) |
NO (1) | NO20083710L (es) |
PE (1) | PE20080319A1 (es) |
TW (1) | TW200808811A (es) |
UY (1) | UY30287A1 (es) |
WO (1) | WO2007118793A1 (es) |
ZA (1) | ZA200807015B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
EP2205608B1 (en) * | 2007-10-18 | 2013-05-08 | Boehringer Ingelheim International GmbH | Preparation of dihydrothieno[3, 2-d]pyrimidines and intermediates used therein |
UA99309C2 (ru) | 2007-10-19 | 2012-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Замещенные пиперидинодигидротиенопиримидины |
WO2009053268A1 (de) * | 2007-10-19 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Neue phenyl-substituierte piperazino-dihydrothienopyrimidine |
US8486948B2 (en) | 2007-10-19 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Piperazinodihydrothienopyrimidine derivatives |
KR20100075930A (ko) | 2007-10-19 | 2010-07-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘 |
US8592400B2 (en) | 2009-02-27 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Drug combinations containing PDE4 inhibitors and NSAIDs |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
CN105037369B (zh) * | 2015-06-23 | 2017-07-07 | 河南师范大学 | 一种吡唑并[5,1‑a]异吲哚‑3‑甲酰胺类化合物的合成方法 |
US11365204B2 (en) | 2017-09-20 | 2022-06-21 | UNION therapeutics A/S | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
CA3079299A1 (en) | 2017-10-23 | 2019-05-02 | Boehringer Ingelheim International Gmbh | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
ES2935615T3 (es) | 2017-12-15 | 2023-03-08 | Union Therapeutics As | Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
JP7198820B2 (ja) | 2017-12-15 | 2023-01-04 | ユニオン・セラピューティクス・アクティエセルスカブ | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 |
CN111712503B (zh) | 2017-12-15 | 2024-04-09 | 联合疗法公司 | 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
CA3234847A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
WO2023104961A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases |
WO2024032673A1 (zh) * | 2022-08-09 | 2024-02-15 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
WO2024068386A1 (en) | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
WO2024067660A1 (zh) * | 2022-09-29 | 2024-04-04 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470336A1 (de) | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
NL124131C (es) | 1963-06-17 | |||
DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE663693A (es) | 1965-03-31 | |||
DE1940572A1 (de) | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
DE2032687A1 (en) | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
FR2082496A5 (es) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
DE2121950A1 (en) | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
DE2750288A1 (de) | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
JPH07330777A (ja) | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ[3,2−d]ピリミジン−4−オン誘導体 |
JPH09301958A (ja) | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
DZ3478A1 (fr) | 2000-10-12 | 2002-04-18 | Boehringer Ingelheim Pharma | Monohydrate cristallin, procede pour sa fabrication et son utilisation pour la fabrication d'un medicament. |
DE10064994A1 (de) | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
ME00412B (me) | 2001-06-22 | 2011-10-10 | Boehringer Ingelheim Pharma | Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka |
US6587548B2 (en) | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
AU2002364211A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
CA2488202C (en) | 2002-06-12 | 2011-03-08 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders |
NZ542097A (en) | 2003-04-29 | 2008-12-24 | Pfizer Ltd | 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
AU2004280575B8 (en) | 2003-10-02 | 2010-05-13 | Dsm Ip Assets B.V. | Production of high levels of DHA in microalgae using modified amounts of chloride and potassium |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
BRPI0608387A2 (pt) * | 2006-04-19 | 2009-12-29 | Boehringer Ingelheim Int | compostos para o tratamento de doenças inflamatórias |
DE602008002912D1 (de) | 2007-04-20 | 2010-11-18 | Glaxo Group Ltd | Tricyclische stickstoffhaltige verbindungen als antibakterielle wirkstoffe |
EP2205608B1 (en) | 2007-10-18 | 2013-05-08 | Boehringer Ingelheim International GmbH | Preparation of dihydrothieno[3, 2-d]pyrimidines and intermediates used therein |
FR2922550B1 (fr) | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
WO2009053268A1 (de) | 2007-10-19 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Neue phenyl-substituierte piperazino-dihydrothienopyrimidine |
CA2702922C (en) | 2007-10-19 | 2018-01-16 | Schering Corporation | Spiro-condensed 1,3,4-thiadiazole derivatives for inhibiting ksp kinesin activity |
US8486948B2 (en) | 2007-10-19 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Piperazinodihydrothienopyrimidine derivatives |
UA99309C2 (ru) | 2007-10-19 | 2012-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Замещенные пиперидинодигидротиенопиримидины |
CL2008003085A1 (es) | 2007-10-19 | 2009-10-09 | Astrazeneca Ab | Compuestos derivados de 4-metil-5-[1-(2-(3-metilfenil)-2h-tetrazol-5-il)etoxi]-4h-1,2,4-triazol-3-il moduladores del receptor mglur5; composiciones farmceuticas que los contienen; compuestos intermediarios; y su uso en la preparacion de un medicamento util en el tratamiento de desordenes neurologicos, psiquiatricos o gastrointestinales. |
KR20100075930A (ko) | 2007-10-19 | 2010-07-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘 |
JP2012519160A (ja) | 2009-02-27 | 2012-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4阻害剤及びnsaidを含有する組み合わせ薬 |
US8592400B2 (en) | 2009-02-27 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Drug combinations containing PDE4 inhibitors and NSAIDs |
-
2006
- 2006-04-19 EP EP06112779A patent/EP1847543A1/de not_active Withdrawn
-
2007
- 2007-04-03 AU AU2007239573A patent/AU2007239573A1/en not_active Abandoned
- 2007-04-03 EP EP07727726A patent/EP2010185B1/de active Active
- 2007-04-03 MX MX2008012915A patent/MX2008012915A/es not_active Application Discontinuation
- 2007-04-03 CN CNA2007800140081A patent/CN101426505A/zh active Pending
- 2007-04-03 JP JP2009505831A patent/JP5214588B2/ja active Active
- 2007-04-03 EA EA200802051A patent/EA200802051A1/ru unknown
- 2007-04-03 KR KR1020087028318A patent/KR20090009885A/ko not_active Application Discontinuation
- 2007-04-03 BR BRPI0710459-6A patent/BRPI0710459A2/pt not_active IP Right Cessation
- 2007-04-03 CA CA002647243A patent/CA2647243A1/en not_active Abandoned
- 2007-04-03 WO PCT/EP2007/053255 patent/WO2007118793A1/de active Application Filing
- 2007-04-16 UY UY30287A patent/UY30287A1/es not_active Application Discontinuation
- 2007-04-17 PE PE2007000470A patent/PE20080319A1/es not_active Application Discontinuation
- 2007-04-18 AR ARP070101646A patent/AR060516A1/es not_active Suspension/Interruption
- 2007-04-18 US US11/736,703 patent/US8114878B2/en active Active
- 2007-04-18 TW TW096113678A patent/TW200808811A/zh unknown
-
2008
- 2008-08-14 ZA ZA200807015A patent/ZA200807015B/xx unknown
- 2008-08-28 NO NO20083710A patent/NO20083710L/no not_active Application Discontinuation
- 2008-09-15 EC EC2008008738A patent/ECSP088738A/es unknown
- 2008-10-17 CO CO08111120A patent/CO6140032A2/es unknown
- 2008-10-22 IL IL194739A patent/IL194739A0/en unknown
-
2012
- 2012-01-04 US US13/343,391 patent/US8604039B2/en active Active
-
2013
- 2013-09-05 US US14/019,019 patent/US8822474B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20080096882A1 (en) | 2008-04-24 |
EP1847543A1 (de) | 2007-10-24 |
KR20090009885A (ko) | 2009-01-23 |
NO20083710L (no) | 2008-11-18 |
JP2010523467A (ja) | 2010-07-15 |
EA200802051A1 (ru) | 2009-04-28 |
BRPI0710459A2 (pt) | 2011-08-16 |
MX2008012915A (es) | 2008-10-15 |
US8822474B2 (en) | 2014-09-02 |
AU2007239573A1 (en) | 2007-10-25 |
ECSP088738A (es) | 2008-10-31 |
EP2010185A1 (de) | 2009-01-07 |
IL194739A0 (en) | 2009-08-03 |
US20140005154A1 (en) | 2014-01-02 |
EP2010185B1 (de) | 2012-06-13 |
ZA200807015B (en) | 2010-01-27 |
TW200808811A (en) | 2008-02-16 |
CO6140032A2 (es) | 2010-03-19 |
WO2007118793A1 (de) | 2007-10-25 |
JP5214588B2 (ja) | 2013-06-19 |
CA2647243A1 (en) | 2007-10-25 |
US20120108534A1 (en) | 2012-05-03 |
UY30287A1 (es) | 2007-11-30 |
CN101426505A (zh) | 2009-05-06 |
US8604039B2 (en) | 2013-12-10 |
US8114878B2 (en) | 2012-02-14 |
AR060516A1 (es) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 | |
NO20083514L (no) | Heterobicykliske sulfonamidderivater for behandling av diabetes | |
PE20091840A1 (es) | Inhibidores de piridilo de la senalizacion hedgehog | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
PE20110136A1 (es) | Compuestos organicos | |
PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
WO2007026920A3 (en) | Amide derivatives as rock inhibitors | |
ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
TW200700069A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | |
EA200900605A1 (ru) | Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов | |
PE20080856A1 (es) | Inhibidores de metaloproteasas de matriz | |
NZ598750A (en) | Therapeutic agent for mood disorders | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
TW200740827A (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
EA200900604A1 (ru) | Производные бензамидов в качестве антагонистов брадикининовых рецепторов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |